Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks
Abcellera Biologics, Inc. (ABCL) has disclosed a new risk, in the Cyber Security category.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Abcellera Biologics, Inc. faces growing risk as it and its vendors adopt generative AI tools that may not align with evolving privacy, security, and data protection standards, increasing exposure to breaches and service disruption. Any actual or perceived AI-related incident, including theft or misuse of confidential or personal data by bad actors, could cause loss of intellectual property, reputational damage, and materially harm its business operations.
The average ABCL stock price target is $7.00, implying 119.44% upside potential.
To learn more about Abcellera Biologics, Inc.’s risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.